[1]
Bush LM, Chaparro-Rojas F, Okeh V, Etienne J. Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy. Infection and drug resistance. 2011:4():177-89. doi: 10.2147/IDR.S15610. Epub 2011 Oct 18
[PubMed PMID: 22114510]
[2]
Bower WA, Yu Y, Person MK, Parker CM, Kennedy JL, Sue D, Hesse EM, Cook R, Bradley J, Bulitta JB, Karchmer AW, Ward RM, Cato SG, Stephens KC, Hendricks KA. CDC Guidelines for the Prevention and Treatment of Anthrax, 2023. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2023 Nov 17:72(6):1-47. doi: 10.15585/mmwr.rr7206a1. Epub 2023 Nov 17
[PubMed PMID: 37963097]
[3]
Park KH, Kim DY, Lee YM, Lee MS, Kang KC, Lee JH, Park SY, Moon C, Chong YP, Kim SH, Lee SO, Choi SH, Kim YS, Woo JH, Ryu BH, Bae IG, Cho OH. Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis. PloS one. 2019:14(2):e0211888. doi: 10.1371/journal.pone.0211888. Epub 2019 Feb 8
[PubMed PMID: 30735536]
[4]
Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. Expert opinion on drug safety. 2019 Nov:18(11):1055-1063. doi: 10.1080/14740338.2019.1665022. Epub 2019 Sep 18
[PubMed PMID: 31500468]
Level 3 (low-level) evidence
[5]
Anderson VR, Perry CM. Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008:68(4):535-65
[PubMed PMID: 18318569]
[6]
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Jul 6:74(12):2089-2114. doi: 10.1093/cid/ciab1013. Epub
[PubMed PMID: 34864936]
[7]
Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000 Mar:117(3):744-51
[PubMed PMID: 10713001]
[8]
Zhu L, Zhang Y, Yang J, Wang Y, Zhang J, Zhao Y, Dong W. Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model. European journal of drug metabolism and pharmacokinetics. 2016 Aug:41(4):395-402. doi: 10.1007/s13318-015-0271-8. Epub 2015 Mar 10
[PubMed PMID: 25753830]
[9]
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clinical pharmacokinetics. 1997 Feb:32(2):101-19
[PubMed PMID: 9068926]
[10]
Ren H, Li X, Ni ZH, Niu JY, Cao B, Xu J, Cheng H, Tu XW, Ren AM, Hu Y, Xing CY, Liu YH, Li YF, Cen J, Zhou R, Xu XD, Qiu XH, Chen N. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. International urology and nephrology. 2017 Mar:49(3):499-507. doi: 10.1007/s11255-017-1507-0. Epub 2017 Jan 20
[PubMed PMID: 28108978]
Level 2 (mid-level) evidence
[11]
Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention. Alimentary pharmacology & therapeutics. 2015 Jun:41(11):1116-31. doi: 10.1111/apt.13172. Epub 2015 Mar 26
[PubMed PMID: 25819304]
[12]
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2019 Nov 15:200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. Epub
[PubMed PMID: 31729908]
Level 1 (high-level) evidence
[14]
Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics. 2016 Nov:138(5):. pii: e20162706. Epub
[PubMed PMID: 27940800]
[15]
Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT, AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014 May:133(5):e1411-36. doi: 10.1542/peds.2014-0563. Epub
[PubMed PMID: 24777226]
[16]
Hayashi PH, Chalasani NP. Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012 Oct 2:184(14):1555-6. doi: 10.1503/cmaj.121270. Epub 2012 Aug 13
[PubMed PMID: 22891207]
[17]
Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001 Oct:21(10 Pt 2):253S-272S
[PubMed PMID: 11642691]
[18]
Ball P. Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Current therapeutic research, clinical and experimental. 2003 Nov:64(9):646-61. doi: 10.1016/j.curtheres.2003.11.003. Epub
[PubMed PMID: 24944413]
[20]
Jun C, Fang B. Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection. BMC cardiovascular disorders. 2021 Sep 28:21(1):470. doi: 10.1186/s12872-021-02258-1. Epub 2021 Sep 28
[PubMed PMID: 34583637]
[21]
Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy. 2007 Nov:27(11):1498-505
[PubMed PMID: 17963459]
[22]
Zhang L, Wei MJ, Zhao CY, Qi HM. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta pharmacologica Sinica. 2008 Dec:29(12):1507-14. doi: 10.1111/j.1745-7254.2008.00908.x. Epub
[PubMed PMID: 19026171]
Level 2 (mid-level) evidence
[23]
Ismail M, Noor S, Harram U, Haq I, Haider I, Khadim F, Khan Q, Ali Z, Muhammad T, Asif M. Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study. BMC health services research. 2018 Oct 10:18(1):762. doi: 10.1186/s12913-018-3579-7. Epub 2018 Oct 10
[PubMed PMID: 30314487]
Level 2 (mid-level) evidence
[24]
Pitman SK, Hoang UTP, Wi CH, Alsheikh M, Hiner DA, Percival KM. Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant? Antibiotics (Basel, Switzerland). 2019 Jul 31:8(3):. doi: 10.3390/antibiotics8030108. Epub 2019 Jul 31
[PubMed PMID: 31370320]
[25]
Colby JM, Patel PC, Fu DY, Rutherford NJ. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines. Clinical biochemistry. 2019 Jun:68():50-54. doi: 10.1016/j.clinbiochem.2019.04.009. Epub 2019 Apr 13
[PubMed PMID: 30991036]
[26]
Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011:120(2):103-10. doi: 10.1159/000334441. Epub 2011 Dec 13
[PubMed PMID: 22156660]
[27]
Lee JH, Lee WY, Yong SJ, Shin KC, Lee MK, Kim CW, Kim SH. A case of levofloxacin-induced anaphylaxis with elevated serum tryptase levels. Allergy, asthma & immunology research. 2013 Mar:5(2):113-5. doi: 10.4168/aair.2013.5.2.113. Epub 2012 Nov 7
[PubMed PMID: 23450078]
Level 3 (low-level) evidence
[28]
Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG : an international journal of obstetrics and gynaecology. 2018 Aug:125(9):1069-1076. doi: 10.1111/1471-0528.15119. Epub 2018 Feb 22
[PubMed PMID: 29319210]
Level 1 (high-level) evidence
[29]
Tanne JH. FDA adds "black box" warning label to fluoroquinolone antibiotics. BMJ (Clinical research ed.). 2008 Jul 15:337(7662):a816. doi: 10.1136/bmj.a816. Epub 2008 Jul 15
[PubMed PMID: 18632714]
[30]
Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug safety. 2011 Oct 1:34(10):839-47. doi: 10.2165/11593110-000000000-00000. Epub
[PubMed PMID: 21879778]
[31]
Jones CB, Fugate SE. Levofloxacin and warfarin interaction. The Annals of pharmacotherapy. 2002 Oct:36(10):1554-7
[PubMed PMID: 12243605]
[32]
Mazzei D, Accardo J, Ferrari A, Primavera A. Levofloxacin neurotoxicity and non-convulsive status epilepticus (NCSE): a case report. Clinical neurology and neurosurgery. 2012 Dec:114(10):1371-3. doi: 10.1016/j.clineuro.2012.03.029. Epub 2012 Apr 30
[PubMed PMID: 22551579]
Level 3 (low-level) evidence
[33]
Sankar A, Swanson KM, Zhou J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration. JAMA network open. 2021 Dec 1:4(12):e2136662. doi: 10.1001/jamanetworkopen.2021.36662. Epub 2021 Dec 1
[PubMed PMID: 34851398]